151 related articles for article (PubMed ID: 37756683)
1. Cascade testing for hereditary cancer: comprehensive multigene panels identify unexpected actionable findings in relatives.
Heald B; Pirzadeh-Miller S; Ellsworth RE; Nielsen SM; Russell EM; Beitsch P; Esplin ED; Nussbaum RL; Pineda-Alvarez DE; Kurian AW; Hampel H
J Natl Cancer Inst; 2024 Feb; 116(2):334-337. PubMed ID: 37756683
[TBL] [Abstract][Full Text] [Related]
2. Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
Caswell-Jin JL; Zimmer AD; Stedden W; Kingham KE; Zhou AY; Kurian AW
J Natl Cancer Inst; 2019 Jan; 111(1):95-98. PubMed ID: 30239769
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
Whitworth PW; Beitsch PD; Patel R; Rosen B; Compagnoni G; Baron PL; Simmons R; Brown EA; Gold L; Holmes D; Smith LA; Kinney M; Grady I; Clark P; Barbosa K; Lyons S; Riley L; Coomer C; Curcio L; Ruiz A; Khan S; MacDonald H; Hughes K; Hardwick MK; Heald B; Munro SB; Nielsen SM; Esplin ED
JAMA Netw Open; 2022 Sep; 5(9):e2232787. PubMed ID: 36136330
[TBL] [Abstract][Full Text] [Related]
4. Germline whole genome sequencing in adults with multiple primary tumors.
Wang Y; Ding Q; Prokopec S; Farncombe KM; Bruce J; Casalino S; McCuaig J; Szybowska M; van Engelen K; Lerner-Ellis J; Pugh TJ; Kim RH
Fam Cancer; 2023 Oct; 22(4):513-520. PubMed ID: 37481477
[TBL] [Abstract][Full Text] [Related]
5. Germline pathogenic variants in cancer risk genes among patients with thyroid cancer and suspected predisposition.
Kamihara J; Zhou J; LaDuca H; Wassner AJ; Dalton E; Garber JE; Black MH
Cancer Med; 2022 Apr; 11(8):1745-1752. PubMed ID: 35174967
[TBL] [Abstract][Full Text] [Related]
6. Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria.
Andoni T; Wiggins J; Robinson R; Charlton R; Sandberg M; Eeles R
Sci Rep; 2022 Feb; 12(1):2507. PubMed ID: 35190596
[TBL] [Abstract][Full Text] [Related]
7. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED
Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755
[TBL] [Abstract][Full Text] [Related]
8. Two unique BAP1 pathogenic variants identified in the same family by panel cascade testing.
Byrne L; Ingalls C; Ansari A; Porteus C; Donenberg TR; Sussman DA; Cebulla CM; Abdel-Rahman MH
Fam Cancer; 2023 Jul; 22(3):307-311. PubMed ID: 36513904
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
10. Cancer predisposition and germline CTNNA1 variants.
Lobo S; Benusiglio PR; Coulet F; Boussemart L; Golmard L; Spier I; Hüneburg R; Aretz S; Colas C; Oliveira C
Eur J Med Genet; 2021 Oct; 64(10):104316. PubMed ID: 34425242
[TBL] [Abstract][Full Text] [Related]
11. Germline testing for homologous recombination repair genes-opportunities and challenges.
Hirsch S; Gieldon L; Sutter C; Dikow N; Schaaf CP
Genes Chromosomes Cancer; 2021 May; 60(5):332-343. PubMed ID: 33078493
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
Samadder NJ; Riegert-Johnson D; Boardman L; Rhodes D; Wick M; Okuno S; Kunze KL; Golafshar M; Uson PLS; Mountjoy L; Ertz-Archambault N; Patel N; Rodriguez EA; Lizaola-Mayo B; Lehrer M; Thorpe CS; Yu NY; Esplin ED; Nussbaum RL; Sharp RR; Azevedo C; Klint M; Hager M; Macklin-Mantia S; Bryce AH; Bekaii-Saab TS; Sekulic A; Stewart AK
JAMA Oncol; 2021 Feb; 7(2):230-237. PubMed ID: 33126242
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Proband Indication for Genetic Testing on the Uptake of Cascade Testing Among Relatives.
Schmidlen TJ; Bristow SL; Hatchell KE; Esplin ED; Nussbaum RL; Haverfield EV
Front Genet; 2022; 13():867226. PubMed ID: 35783293
[TBL] [Abstract][Full Text] [Related]
14. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing.
Terraf P; Pareja F; Brown DN; Ceyhan-Birsoy O; Misyura M; Rana S; O'Reilly E; Carlo MI; Aghajanian C; Liu Y; Derakhshan F; Jayakumaran G; Weigelt B; Walsh M; Stadler Z; Offit K; Ladanyi M; Robson M; Zehir A; Reis-Filho JS; Mandelker D
Ann Oncol; 2022 Apr; 33(4):426-433. PubMed ID: 35074424
[TBL] [Abstract][Full Text] [Related]
16. Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort.
Karpel H; Manderski E; Pothuri B
Int J Gynecol Cancer; 2023 Jul; 33(7):1044-1050. PubMed ID: 36889816
[TBL] [Abstract][Full Text] [Related]
17. Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives.
Bennett S; Alexander E; Fraser H; Bowers N; Wallace A; Woodward ER; Lalloo F; Quinn AM; Huang S; Schlecht H; Evans DG
Eur J Hum Genet; 2021 May; 29(5):861-871. PubMed ID: 33654310
[TBL] [Abstract][Full Text] [Related]
18. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
19. Germline Testing for the Evaluation of Hereditary Cancer Predisposition.
Ceyhan-Birsoy O
Clin Lab Med; 2022 Sep; 42(3):497-506. PubMed ID: 36150826
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study.
Tavano F; Gioffreda D; Fontana A; Palmieri O; Gentile A; Latiano T; Latiano A; Latiano TP; Scaramuzzi M; Maiello E; Bazzocchi F; Perri F
Mol Med; 2023 Jan; 29(1):14. PubMed ID: 36717774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
